首页|18F-FDG PET/CT显像在噬血细胞性淋巴组织细胞增生症中的应用价值

18F-FDG PET/CT显像在噬血细胞性淋巴组织细胞增生症中的应用价值

扫码查看
目的 探讨18F-FDG PET/CT显像对噬血细胞性淋巴组织细胞增生症(HLH)的病因诊断能力.方法 回顾性分析2017年1月至2023年1月于济宁医学院附属医院行18F-FDG PET/CT显像的49例初诊HLH患者(男32例、女17例,年龄19~61岁).观察并记录PET/CT显像结果及临床资料.以病理学检查及临床随访结果为标准,计算PET/CT、PET、CT显像对HLH病因的诊断效能;采用x2检验、两独立样本t检验、Mann-Whitney U检验比较血液系统肿瘤相关性HLH与非血液系统肿瘤相关性HLH间PET/CT显像特征及临床指标的差异;采用多因素logistic回归分析血液系统肿瘤继发HLH的预测因素;采用ROC曲线分析计算血液系统肿瘤患者淋巴结SUVmax、可溶性CD25(sCD25)预测继发HLH的AUC和最佳阈值.结果 PET/CT、PET、CT在HLH病因诊断中的灵敏度、特异性、准确性、阳性预测值、阴性预测值分别为85.7%(30/35)、8/10、84.4%(38/45)、93.8%(30/32)、8/13;77.1%(27/35)、6/10、73.3%(33/45)、87.1%(27/31)、6/14;62.9%(22/35)、5/10、60.0%(27/45)、81.5%(22/27)、5/18.不同病因组间淋巴结分布及边界、肝脾及骨骼病变特征、淋巴结及肝、脾、骨骼SUVmax、性别、年龄、WBC、中性粒细胞(ANC)、PLT、乳酸脱氢酶(LDH)、总胆红素(TBIL)、C反应蛋白(CRP)、sCD25差异均有统计学意义(x2值:3.91~9.66,t值:3.75~7.90,z值:3.82~4.01,均P<0.05).淋巴结SUVmax、sCD25为血液系统肿瘤继发HLH的预测因素[比值比(OR):1.28(95%CI:1.09~1.72)、1.56(95%CI:1.17~2.49),P 值:0.004、0.013];预测最佳阈值分别为12.6、40 028 ng/L,AUC 分别为 0.87、0.76,灵敏度和特异性分别为 88.6%(31/35)和 8/10、65.7%(23/35)和7/10;两者结合后AUC为0.83,灵敏度和特异性分别为74.3%(26/35)和9/10.结论 18F-FDG PET/CT显像对HLH病因诊断具有较高价值;淋巴结SUVmax、sCD25为血液系统肿瘤继发HLH的预测因素.
Value of 18F-FDG PET/CT imaging in hemophagocytic lymphohistiocytosis
Objective To explore the diagnostic value of 18F-FDG PET/CT imaging in etiology of patients with hemophagocytic lymphohistiocytosis(HLH).Methods Retrospective analysis was performed on 49 patients newly diagnosed as HLH(32 males,17 females;age 19-61 years)who received 18F-FDG PET/CT imaging in Affiliated Hospital of Jining Medical University from January 2017 to January 2023.PET/CT images and clinical parameters were observed and recorded.Based on the pathological examination and clinical follow-up results,diagnostic efficacies for HLH etiology of PET/CT,PET and CT imaging were calculated.x2 test,independent-sample t test and Mann-Whitney U test were used to compare the differ-ences between hematologic tumors associated HLH and non-hematologic tumor associated HLH.Multivariate logistic regression was used to analyze the predictors of secondary HLH in hematologic tumors.ROC curve analy-sis was used to calculate AUCs and optimal threshold of lymph node SUVmax and soluble CD25(sCD25)to predict secondary HLH in patients with hematologic tumors.Results The sensitivity,specificity,accura-cy,positive predictive value and negative predictive value of PET/CT,PET and CT in the etiological diag-nosis of HLH were 85.7%(30/35),8/10,84.4%(38/45),93.8%(30/32),8/13;77.1%(27/35),6/10,73.3%(33/45),87.1%(27/31),6/14;62.9%(22/35),5/10,60.0%(27/45),81.5%(22/27),5/18,respectively.There were differences in lymph node distribution and boundary,liver and spleen and bone lesions,SUVmax of lymph node and liver and spleen and bone,gender,age,WBC,neutrophil(ANC),PLT,lactate dehydrogenase(LDH),total bilirubin(TBIL),C-reactive protein(CRP)and sCD25 between different etiology groups(x2 values:3.91-9.66,t values:3.75-7.90,z values:3.82-4.01,all P<0.05).SUVmax of lymph nodes and sCD25 were predictive factors for secondary HLH of hematological tumors(odds ratio(OR):1.28(95%CI:1.09-1.72),1.56(95%CI:1.17-2.49),P values:0.004,0.013).The optimal thresholds were 12.6 and 40 028 ng/L,with the AUC of 0.87 and 0.76,with the sen-sitivity and specificity of 88.6%(31/35)and 8/10,65.7%(23/35)and 7/10,respectively.The combined AUC was 0.83 and the sensitivity and specificity were 74.3%(26/35)and 9/10.Conclusions 18F-FDG PET/CT imaging is of high value for the diagnosis of the cause of HLH.SUVmax of lymph node and sCD25 are predictive factors for secondary HLH of hematologic tumors.

Lymphohistiocytosis,hemophagocyticPositron-emission tomographyTomography,X-ray computedFluorodeoxy glucose F18

党娜、孙英、董有文、张谷青、高明

展开 >

济宁医学院附属医院医学影像科,济宁 272000

济宁医学院附属医院妇产科,济宁 272000

淋巴组织细胞增多症,嗜血细胞性 正电子发射断层显像术 体层摄影术,X线计算机 氟脱氧葡萄糖F18

2024

中华核医学与分子影像杂志
中华医学会

中华核医学与分子影像杂志

CSTPCD北大核心
影响因子:1.107
ISSN:2095-2848
年,卷(期):2024.44(7)
  • 2